Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut

Group 1 - Agomab Therapeutics shares experienced an approximately 8% decline during their Nasdaq debut [1] - The company, based in Belgium, is currently valued at $716.4 million following its initial public offering [1]